Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.

What´s up at IZB

Sehr geehrte(r) Frau/Herr Titel ,

Invitris GmbH, led by Dr. Patrick Großmann (CEO) and Dr. Kilian Vogele (CTO), is another dedicated team that has moved into the IZB. We warmly welcome them to our location. Another start-up will soon follow.

With the participation of the Minister President Dr. Markus Söder, the long-awaited groundbreaking ceremony for the construction of the subway, which will then connect the science location Garching with the IZB in Martinsried, has now taken place. Good things come to those who wait.

The year has already begun with many interesting events at the IZB. On March 16, 2023, our popular Biotech Press Lounge will take place. We receive new registrations every day. If you still want to be part of it, feel free to register. We look forward to seeing you continue to take advantage of the networking opportunity at IZB.

With best regards

Yours

Dr. Peter Hanns Zobel
Managing Director IZB

IZB News

Groundbreaking ceremony with Mayor Hermann Nafziger, Kerstin Schreyer, Bavarian Economic Policy Spokeswoman, District Administrator Christoph Göbel, Minister President Dr. Markus Söder, Markus Blume, State Minister for Science and the Arts, Christian Bernreiter for Housing, Construction and Transportation, Managing Director Engineering and Turnkey Construction of LEONHARD WEISS Steffen Schönfeld and PMG Managing Director Dr. Dimitri Steinke.

IZB:

Expansion of the Munich "science line" has started

The extension, which was celebrated with an official groundbreaking ceremony, will connect the IZB in Martinsried to the Munich subway system.

Origenis:

US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease

NEU-723, a best-in-class brain-penetrant LRRK2 inhibitor, is the first program of the biotech company, co-founded by IZB start-up Origenis GmbH, to enter the clinic.

Invitris:

Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris

The start-up uses its platform technology to develop highly effective protein-based drugs against infectious diseases.

IZBrunch Video from Feb 16, 2023

Networking event at the IZB

Prof. Dr. Marion Subklewe, Head of Immunotherapy in Hematology at the LMU Hospital of the University of Munich, and Dr. Garwin Pichler, CEO PreOmics GmbH presented their exciting research and practice.

Save the date: March 16, 2023

Biotech Press Lounge at the IZB

Looking forward to our speaker: Dr. Karl Nägler, Wellington Partners; Dr. Daniel Reichart, Postdoctoral Fellow Department of Genetic Harvard Medical School and XTransplant Consultant as well as Heimo Adamski, 4GENE

Save the date: July 13, 2023

Life Science Pitch Day at the IZB

Present your project to over 30 investors and establish early contacts in the venture capital scene of the life science industry. Co-partners are HTGF, Bayer, Boehringer Ingelheim and MEDICE.

LMU:

When life begins too early

Infections are under the most common causes of death in premature infants. Markus Sperandio studies the immune system in those babies and what makes them so vulnerable to infections.

Formycon:

Enno Spillner to join Formycon as CFO

The industry expert and IZB alumnus will leave Evotec to drive the implementation of the growth strategy of biosimilar developer Formycon..

Contact

Susanne Simon
Head of Public Relation
Phone: 089/55 279 48-17
Mail: izb@izb-online.de

Location Martinsried:

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Location Weihenstephan:

Fördergesellschaft IZB mbH
Lise-Meitner-Straße 30
85354 Freising/Weihenstephan